Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia's stock is up 6% on data from an early-stage trial for its Crispr therapy
08:38am, Friday, 16'th Sep 2022
Shares of Intellia Therapeutics Inc. NTLA, +7.36% gained 6.5% in premarket trading on Friday after the company and Regeneron Pharmaceuticals Inc. REGN, +1.18% announced positive data from an ongoing P
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
07:15am, Friday, 16'th Sep 2022
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. The update could send CRISPR stocks flying.
CAMBRIDGE, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
02:33pm, Thursday, 01'st Sep 2022 Benzinga
Upgrades
For iQIYI Inc (NASDAQ:IQ), UBS upgraded the previous rating of Neutral to Buy. For the second quarter, iQIYI had an EPS of $0.01, compared to year-ago quarter EPS of $0.27. At the moment, the
Expert Ratings for Intellia Therapeutics
01:18pm, Thursday, 01'st Sep 2022 Benzinga
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
1
Where Intellia Therapeutics Stands With Analysts
01:13pm, Thursday, 01'st Sep 2022 Benzinga
Over the past 3 months, 5 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understan
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
09:56am, Wednesday, 24'th Aug 2022 Benzinga
Gainers
Windtree Therapeutics, Inc. (NASDAQ: WINT) shares jumped 55.2% to close at $0.70 on Tuesday after the company announced it has entered into a global licensing agreement for the development an
Macy's, Palo Alto Networks And Other Big Gainers From Tuesday
09:19am, Wednesday, 24'th Aug 2022 Benzinga
U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session.
Aerie Pharmaceuticals, Inc. (NA
Can Intellia One-Up Alnylam In Transthyretin Amyloidosis?
04:28pm, Tuesday, 23'rd Aug 2022
Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR.
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium
01:59pm, Tuesday, 23'rd Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l
7 Stock Price Predictions That Are Actually Worth Listening To
06:10am, Friday, 12'th Aug 2022
Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside caref
Expert Ratings for Intellia Therapeutics
03:09pm, Friday, 05'th Aug 2022 Benzinga
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
1
0
0
Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday
06:02pm, Thursday, 04'th Aug 2022 Benzinga
AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days.
AMTD IDEA Group (NASDAQ: AMTD) fell 36.2% to $3.9709 after dropp
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
05:43pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
